川宁生物：今年合成生物学基地仍在产能爬坡期

Core Viewpoint - The company is focusing on the commercialization of synthetic biology products, which are currently in a ramp-up phase of production, with improved order conditions compared to the previous year [1] Group 1: Synthetic Biology Products - The synthetic biology products currently in mass production include resveratrol, 5-hydroxytryptophan, ergothioneine, squalene, and inositol [1] - As of the third quarter of 2025, the revenue from synthetic biology products is projected to be 44.8 million yuan [1] - The company adheres to a dual-driven strategy of "biological fermentation + synthetic biology" to continuously optimize production processes [1] Group 2: Production Capacity and Orders - The synthetic biology base is still in the capacity ramp-up phase [1] - There has been an improvement in order conditions compared to the same period last year [1] - The company is actively promoting the commercialization process of synthetic biology products [1]